Coyne Terrance P. 4

What Happened

• Terrance P. Coyne, Executive Vice President & Chief Financial Officer of Royalty Pharma (RPRX), sold a total of 34,791 Class A ordinary shares in open‑market transactions on April 28, 2026. The sales were reported as two disposals: 32,916 shares for $1,638,506 and 1,875 shares for $93,335, for a combined proceeds of $1,731,841. The reported weighted average price was $49.78 per share (individual sale prices ranged $49.46–$50.18).

Key Details

• Transaction date: 2026-04-28; Filing date (Accession): 2026-04-30 — filed within the typical two‑business‑day Form 4 window.
• Reported prices: weighted avg $49.78; range $49.46–$50.18 (footnote states multiple execution prices).
• Plan: All sales were made pursuant to a 10b5-1 trading plan adopted by Coyne on August 8, 2025.
• Shares owned after transaction: the filing excerpt does not list Coyne’s remaining direct Class A share count. The filing notes additional holdings via exchangeable interests equal to 6,448,180 Class A shares (RPI US Partners 2019, LP) and 1,807,277 Class A shares (Class E shares of RPH, subject to vesting).

Context

• These were sales (not purchases or exercises) effected under a 10b5-1 plan, which are pre‑arranged trading plans commonly used to establish an automated, rule‑based selling schedule and are generally considered routine. This type of filing reports insider activity but does not, by itself, indicate the insider’s view of the company’s prospects.